Keros Therapeutics (KROS) PT Raised to $45 at Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Joseph Catanzaro raised the price target on Keros Therapeutics (NASDAQ: KROS) to $45.00 (from $35.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
